Regulatory T Cell (Treg)
CD4+CD25hiFOXP3+ regulatory T cells are the central cellular mechanisms of immunological self-tolerance — 5–10% of peripheral CD4+ T cells that actively monitor and restrain immune responses through IL-10, TGF-β, CTLA-4 trans-endocytosis, IL-2 deprivation, adenosine generation (CD39/CD73), and direct granzyme B-mediated killing. Loss of FOXP3 causes IPEX — fatal neonatal multi-organ autoimmunity. Excess in tumours promotes immune evasion; depletion by anti-CTLA-4 therapy reinvigorates anti-tumour immunity.
Overview
Regulatory T cells (Tregs) are a specialized subset of CD4+ T lymphocytes defined by constitutive co-expression of CD4, CD25 (IL-2Rα), and the master transcription factor FOXP3 (forkhead box P3). They comprise 5–10% of peripheral CD4+ T cells in humans and are the central cellular mechanisms of immunological self-tolerance.
Tregs are not simply suppressive bystanders: they actively monitor and restrain immune responses through a diverse toolkit of contact-dependent and contact-independent mechanisms, maintaining the delicate balance between protective immunity and destructive autoimmunity. This dual role — too few Tregs leads to autoimmunity; too many leads to immune evasion in cancer and chronic infection — makes them important targets in both autoimmune disease therapy (Treg enhancement) and cancer immunotherapy (Treg depletion).
Structure — Surface Markers
| Marker | Expression | Function / Significance |
|---|---|---|
| CD4 | Constitutive | MHC-II co-receptor; carries Lck; defines T helper lineage |
| CD25 (IL-2Rα) | Constitutively high | High-affinity IL-2R subunit; ~100× higher IL-2 affinity than dimeric IL-2R; "IL-2 sink" |
| FOXP3 | Nuclear; constitutive | Master TF; represses IL-2, IFN-γ, IL-17; induces CD25, CTLA-4; 431-aa forkhead protein |
| CD127 (IL-7Rα) | Low (inverse to FOXP3) | Clinical surrogate for FOXP3; used to sort Tregs (CD4+CD25+CD127low) |
| CTLA-4 (CD152) | Constitutively high | Higher CD80/86 avidity than CD28 (Kd 0.4 µM vs 4 µM); trans-endocytosis of CD80/86 from APCs |
| CD39 (NTPDase1) | + | Converts extracellular ATP/ADP → AMP; pair with CD73 |
| CD73 | + | Converts AMP → adenosine; adenosine → A2AR → immunosuppression |
| Helios (IKZF2) | tTreg marker | Marks thymic-origin Tregs; pTregs are Helios− |
| CXCR5 (Tfr) | Follicular Treg subset | Follicular regulatory T cells (Tfr); CXCR5+FOXP3+; control GC reactions with Tfh |
| GITR (TNFRSF18) | Constitutive | Glucocorticoid-induced TNFR; agonism overcomes Treg suppression (anti-tumor strategy) |
Function — FoxP3 Axis and Suppression Mechanisms
Treg activation (TCR:self-pMHC-II + IL-2 via CD25)
│
▼
FOXP3 maintains suppressive program:
Represses: IL-2, IFN-γ, IL-4, IL-17
Induces: CD25, CTLA-4, Helios, GITR
│
▼
Seven Suppression Mechanisms:
1. Inhibitory cytokines
├──► IL-10 → DCs: ↓CD80/86, ↓MHC-II, ↓IL-12 → block Teff priming
├──► TGF-β → Teff: ↓proliferation, ↓IFN-γ; → B cells: IgA CSR
└──► IL-35 → "infectious tolerance" converts Teff to Tr35 suppressors
2. CTLA-4 trans-endocytosis
CTLA-4 (Treg) captures and internalises CD80/CD86 from APC surface
→ depletes co-stimulatory ligands available to effector T cells
→ CD28 signaling in Teff cells impaired
3. IL-2 deprivation ("IL-2 sink")
CD25hi Tregs consume IL-2 from microenvironment
→ effector T cells starved of survival/proliferation cytokine
4. cAMP transfer
Tregs contain high cAMP → transfer to Teff via connexin-43 gap junctions
→ PKA → ↓IL-2 transcription + ↑ICER repressor
5. Adenosine pathway
CD39 (ATP → AMP) + CD73 (AMP → adenosine)
Adenosine → A2AR (Gαs) on T cells/DCs/NK cells
→ ↑cAMP → suppress TCR signaling and cytotoxicity
6. Granzyme B-mediated killing (perforin-independent)
Direct elimination of DCs, Teff cells, NK cells in tumor microenvironment
7. TIM-1/TIM-4 direct contact suppression
Lifecycle / Differentiation — tTreg vs pTreg
=== Thymic Tregs (tTreg) ===
DP thymocyte with HIGH-AFFINITY self-TCR
(above positive selection, below deletion threshold)
│
▼
Signals: TCR:self-pMHC-II (avidity) + CD28 + IL-2/IL-15
→ FOXP3 induction via NFAT → FOXP3 promoter
→ CNS2 demethylation (TSDR: Treg-specific demethylated region)
→ Stable, heritable FOXP3 expression
│
▼
Helios+ tTreg: stable even in inflammatory conditions
Represent ~60–70% of peripheral Tregs
=== Peripheral Tregs (pTreg) ===
Naive peripheral CD4+ T cell
│
▼
Tolerogenic conditions: TGF-β + IL-2
+ Retinoic acid (gut CD103+ cDC2s, dietary vitamin A → ALDH1A1)
→ Smad2/3 + NFAT → FOXP3 induction
→ Helios− pTreg (FOXP3+RORγt+ in gut lamina propria)
│
▼
Peripheral tolerance to:
- Commensal bacteria (gut pTregs, microbiome-induced)
- Dietary antigens
- Self-antigens not seen in thymus
=== Stability and Plasticity ===
Stable Tregs (CNS2 demethylated): maintain FOXP3 in inflammation
Plastic Tregs (CNS2 methylated): FOXP3 loss under IL-6/IL-1β/TNF-α
→ "ExTreg" Th17-like cells: contribute to autoimmune flares
Pathology
IPEX Syndrome — FOXP3 loss of function
X-linked recessive loss-of-function mutations in FOXP3 (Xp11.23) → absent tTreg development → neonatal multi-organ autoimmunity: type 1 diabetes mellitus, autoimmune thyroiditis, severe eczema, life-threatening enteropathy (villous atrophy, diarrhoea), hemolytic anemia. Without haematopoietic stem cell transplant (HSCT), most patients die in infancy. HSCT (if HLA-matched sibling available) is curative. Rapamycin (mTOR inhibitor) bridges to HSCT by preferentially expanding Tregs.
CTLA-4 Haploinsufficiency
Autosomal dominant CTLA4 mutations → insufficient CTLA-4 → impaired Treg suppression → lymphocytic infiltration of lungs, CNS, and GI tract; autoimmune cytopenias; resembles IPEX-like syndrome but milder. Abatacept (CTLA-4-Ig fusion protein) replaces CTLA-4 function and is the treatment of choice.
Autoimmune diseases — Treg dysfunction
Treg dysfunction documented in type 1 diabetes (↓Treg numbers and function in pancreatic lymph nodes); multiple sclerosis (Tregs fail to suppress myelin-reactive Th17 in CNS); rheumatoid arthritis (Tregs in joints but impaired by TNF-α); IBD (colonic Treg FOXP3 instability under bacterial dysbiosis). Low-dose IL-2 therapy (expanding Tregs preferentially over Teffs) is in clinical trials for T1DM, SLE, IBD, and GVHD.
Cancer — Treg-mediated immune evasion
Tumour-infiltrating Tregs recruited by CCL17/CCL22 (CCR4-expressing Tregs) suppress anti-tumour CTL responses. High Treg:CTL ratios in tumour microenvironments correlate with poor prognosis in ovarian cancer, colorectal cancer, and lung adenocarcinoma. CTLA-4 blockade (ipilimumab) depletes tumour-infiltrating Tregs via ADCC (Tregs are the dominant CTLA-4-expressing cells in tumours) and reinvigorates CTL responses.
Graft-versus-Host Disease (GVHD)
Donor Tregs suppress alloreactive donor T cells after haematopoietic stem cell transplantation (HSCT); Treg depletion or dysfunction → acute GVHD (liver, gut, skin). Adoptive infusion of donor Tregs (ex vivo-expanded CD4+CD25+CD127low Tregs) is a clinical strategy to prevent GVHD without impairing graft-versus-leukaemia (GVL) effect — one of the most promising cell therapies for GVHD prevention.
Therapeutic Manipulation of Tregs
| Strategy | Mechanism | Clinical application |
|---|---|---|
| Low-dose IL-2 therapy | IL-2 preferentially expands Tregs over Teffs at low dose (CD25hi Tregs have 100× higher IL-2 affinity); promotes FOXP3 stability | Phase 2/3 trials: Type 1 diabetes (ITACA, DIABIL-2), SLE, IBD, GVHD prevention; aldesleukin (Proleukin) at low dose (1 MIU/m²) vs high dose used for cancer |
| CTLA-4 blockade (ipilimumab, tremelimumab) | Anti-CTLA-4 antibody depletes tumour-infiltrating Tregs (Fc-mediated ADCC via tumour macrophages expressing FcγRIII); reinvigorates anti-tumour CTL | FDA-approved: melanoma, RCC, NSCLC (ipilimumab + nivolumab); the dominant mechanism for solid tumour efficacy may be Treg depletion rather than CTL checkpoint reversal |
| Adoptive Treg transfer | Ex-vivo expansion of CD4+CD25+CD127low Tregs (1000×) using anti-CD3/CD28 beads + IL-2; infused donor Tregs suppress alloreactive T cells | ONE Study (renal transplant), THRio (GvHD prevention); ~2×10⁸ Tregs per infusion; CAR-Tregs (anti-HLA-A2 CAR to direct antigen-specificity) in clinical development |
| mTOR inhibition (rapamycin) | mTOR signaling is required for effector T cell proliferation but Tregs are relatively mTOR-independent (FOXP3 drives alternative metabolic programs); net effect: Treg expansion relative to Teffs | Transplant immunosuppression; IPEX bridging to HSCT; investigational in autoimmunity; combination with low-dose IL-2 synergistic |
| Vitamin D supplementation | 1,25(OH)₂D₃ (calcitriol) binds VDR in T cells → upregulates FOXP3 transcription; promotes tolerogenic DC phenotype → pTreg induction; inhibits Th1/Th17 differentiation | Observational: Vitamin D deficiency associated with autoimmune disease (MS, T1D, IBD) and Treg insufficiency; supplementation trials ongoing in MS, SLE |
| Anti-CCR4 (mogamulizumab) | Depletes CCR4+ Tregs (and Th2 cells); Fc-mediated ADCC; CCR4 is the primary chemokine receptor driving Treg tumour infiltration | FDA-approved: CTCL (cutaneous T-cell lymphoma); combination with PD-1 blockade in clinical trials for solid tumours to relieve Treg-mediated immune suppression |
Cross-Atlas Connections
References
- Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 7th ed. W.W. Norton; 2022. ncbi.nlm.nih.gov
- Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. Garland Science; 2017. garlandscience.com
- Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-64. doi:10.1146/annurev.immunol.25.022106.141623
- Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th ed. Elsevier; 2018.